Zentalis pharmaceuticals announces inducement grants under nasdaq listing rule 5635(c)(4)

San diego, april 01, 2025 (globe newswire) -- zentalis® pharmaceuticals, inc. (nasdaq: zntl), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class wee1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on april 1, 2025, the compensation committee of zentalis' board of directors granted non-qualified stock options to purchase an aggregate of 140,000 shares of the company's common stock to three (3) newly hired employees. the stock options were granted under the zentalis pharmaceuticals, inc. 2022 employment inducement incentive award plan (2022 inducement plan) as an inducement material to each such individual entering into employment with zentalis in accordance with nasdaq listing rule 5635(c)(4).
NDAQ Ratings Summary
NDAQ Quant Ranking